地氯雷他定与咪唑斯汀治疗慢性荨麻疹的疗效和安全性比较

目的 :评价地氯雷他定与咪唑斯汀比较治疗慢性荨麻疹的临床疗效和安全性。方法 :采用随机对照临床试验 ,试验组每日口服地氯雷他定 5mg,疗程 1 4d;对照组每日口服咪唑斯汀 1 0mg,疗程 1 4d。结果 :共治疗 94例 ,试验组 49例 ,对照组 45例。患者主、客观症状观察项目平均积分于服药第 7、1 4天均有下降 ,但两组比较均无统计学意义。治疗后第 1 4天总有效率为试验组 85 7% ,对照组 82 2 % ,两组比较差异无显著性 (P >0 0 5 )。不良反应发生率试验组为 1 0 2 % ,对照组为 1 3 3 % ,两组比较差异无显著性 (P >0 0 5 )。两组用药前后血尿常规、肝肾功能、心电图均无有意义的变化。结论 :地氯雷他定和咪唑斯汀都是治疗慢性荨麻疹安全有效的药物

Efficacy and Safety Comparison between Desloratadine and Mizolastine in Treatment of Chronic Urticaria

Objective:To evaluate the efficacy and safety of desloratadine in the treatment of chronic urticaria in comparison with mizolastine. Methods:A randomly comparative study was conducted. The patients were randomly divided into two groups: treated with desloratadine(5 mg) or mizolastine(10 mg) once daily for 14 days. Results:94 patients completed the trial, including 49 cases in desloratadine group and 45 cases in mizolastine group. All symptom scores decreased significantly after treatment in both groups, but the score decrease had no significant difference between two groups. The effective rate of desloratadine and mizolastine were 85.7% and 82.2% respectively, no statistical difference was observed between the two groups (P>0.05) after 14 days treatment. The incidences of adverse reaction of desloratadine and mizolastine were 10.2% and 13.3% respectively. There was no statiastically difference between two groups (P>0.05). Blood and urine routine tests, liver and renal functions and ECG showed no significant changes after treatment in the two groups. Conclusion:Desloratadine and mizolastine are effective agents in the treatment of chronic urticaria.